Retatrutide Side Effects: What the Phase 2 Data Shows

What Retatrutide Side Effects Look Like in the Trial Data

Retatrutide side effects are overwhelmingly gastrointestinal, dose-dependent and concentrated during dose escalation, with nausea, diarrhoea, vomiting and constipation accounting for most reports across Phase 2 and Phase 3 trials. A newer signal, dysesthesia (abnormal skin sensation), appears at meaningful rates only at the highest doses. Serious adverse events remain rare and roughly comparable to placebo.

This breakdown pulls directly from the published trial data rather than anecdote. If you are researching this compound, a vendor-neutral rundown of recommended sources sits on our sources page, and everything below is intended for research use, not a substitute for a conversation with your own clinician.

Gastrointestinal Side Effects: The Numbers From Phase 2 and Phase 3

Gastrointestinal symptoms are the single largest category of retatrutide side effects, hitting roughly a third to just under half of trial participants at the higher doses, and they cluster tightly around the weeks when the dose is being raised rather than persisting once a stable dose is reached.

In the Phase 2 obesity trial, transient, mostly mild-to-moderate gastrointestinal events were the most frequently reported adverse events, occurring primarily during dose escalation, and the same trial recorded the headline 24.2% mean weight reduction at 12 mg versus 2.1% on placebo at 48 weeks. Jastreboff 2023

The Phase 2 type 2 diabetes trial found a similar pattern from the metabolic side: mild-to-moderate gastrointestinal adverse events, including nausea, diarrhoea, vomiting and constipation, were reported in 35% of retatrutide participants against 13% on placebo, with incidence climbing as high as 50% in the fast-escalation 8 mg arm. Rosenstock 2023

A 2025 meta-analysis pooling the available randomised trials confirmed the dose-response shape of this signal: the 4 mg dose showed no significant increase in adverse events over placebo, while the 12 mg dose carried a relative risk of 1.34 for any adverse event. Abdrabou 2025 In the larger Phase 3 TRIUMPH-1 programme, nausea ranged from 28.6% to 42.4% across the 4 to 12 mg doses versus 14.8% on placebo, diarrhoea ran 25.2% to 32.0% versus 13.5%, and vomiting reached 10.6% to 25.3% versus 4.8%. None of that means the drug is poorly tolerated in absolute terms; it means the side effect burden scales with dose the way most incretin therapies do.

Dysesthesia: The Side Effect Unique to Retatrutide

Dysesthesia, an abnormal skin sensation described as tingling, prickling or altered touch sensitivity, is the one side effect that separates retatrutide from semaglutide and tirzepatide. It showed up at roughly 1 in 5 participants at the 12 mg dose in Phase 3, was not prominent in earlier Phase 2 data, and appears linked to the drug's added glucagon receptor activity.

Extended TRIUMPH-1 data through 104 weeks put dysesthesia and urinary tract infections at around one in ten patients on the highest doses, generally mild-to-moderate and mostly resolving during ongoing treatment rather than forcing discontinuation. This is a genuinely new signal in the triple-agonist class, distinct from the gastrointestinal pattern shared with older GLP-1 drugs, and it is the one to flag if you notice unusual skin sensations after a dose increase.

Heart Rate Changes and Cardiovascular Safety

Retatrutide produces a modest, reversible rise in resting heart rate, typically 5 to 10 beats per minute, that scales with dose, peaks around week 24 and declines from there. No major adverse cardiovascular events have been reported in the published trials, and the mechanism sits with the drug's glucagon receptor component rather than the GLP-1 or GIP pathways.

The Phase 2 obesity trial that established the weight-loss headline also tracked this heart rate signal alongside the primary endpoint, and the pattern held across dose groups without translating into serious cardiac events. Jastreboff 2023 If you already carry a cardiovascular risk factor, that resting heart rate shift is worth discussing directly rather than assuming it will resolve on its own.

Serious Adverse Events: Pancreatitis, Thyroid and Gallbladder Risk

Serious adverse events with retatrutide have so far tracked at rates comparable to placebo, around 4% in each arm of Phase 2, which is the strongest evidence available that the rare serious events reported were not clearly caused by the drug itself. Pancreatitis, thyroid C-cell tumours and gallbladder disease are the three risks worth understanding individually rather than lumping together.

One case of acute pancreatitis occurred at the 12 mg dose in Phase 2, alongside asymptomatic elevations in amylase and lipase in other participants who never developed pancreatic symptoms. A related Phase 2a substudy in participants with metabolic dysfunction-associated steatotic liver disease reported liver fat reductions of 22.8% and 24.2% at the 8 and 12 mg doses over 48 weeks, underscoring that the metabolic benefit and the monitoring burden move together. Sanyal 2024

Thyroid C-cell tumours are a class-wide concern that originates in rodent studies of GLP-1 agonists; no human case of medullary thyroid carcinoma or C-cell hyperplasia has been reported in any retatrutide trial to date. Gallbladder events (gallstones, cholecystitis) occurred at low rates comparable to placebo, though rapid weight loss itself is an independent risk factor for gallstone formation regardless of which drug drove the loss.

Dosing, Titration and Why Slow Escalation Matters

Trial doses of retatrutide have ranged from 0.5 mg up to 12 mg once weekly, and the single biggest variable separating people who tolerate treatment well from those who discontinue early is the pace of dose escalation, not the final maintenance dose itself. Skipping planned titration steps has been associated with roughly double the gastrointestinal symptom rate compared with a gradual schedule.

Discontinuation due to adverse events ran 7% to 9% in Phase 2 and climbed to 12% to 18% in longer Phase 3 trials, with the 12 mg arm of TRIUMPH-1 showing 11.3% discontinuation against 4.9% on placebo. That gap narrows considerably at lower, slower-titrated doses. Always work with a qualified clinician before making changes to your health protocol, particularly around how quickly a dose is raised.

Who Should Avoid Retatrutide

Retatrutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and for anyone with severe renal impairment or uncontrolled thyroid disease. Extra caution applies with a prior history of pancreatitis, gallbladder disease or severe gastrointestinal disease including gastroparesis.

Baseline blood work before starting typically covers TSH, free T4, amylase, lipase, liver enzymes and kidney function, giving you a reference point to compare against if symptoms appear later. None of this replaces a full medical history review with a qualified clinician, especially given how dose-dependent the side effect pattern is.

How Retatrutide Compares to Semaglutide and Tirzepatide on Tolerability

Retatrutide's overall side effect profile sits close to semaglutide and tirzepatide on gastrointestinal symptoms, but its added glucagon receptor activity introduces two effects the older drugs do not show at the same magnitude: the dysesthesia signal and a more pronounced dose-dependent heart rate rise.

A qualitative study of Phase 2 participants found that 31 of 36 people on retatrutide reported positive lifestyle impacts from treatment, while 2 reported reduced social or leisure activity tied to treatment-related side effects or new eating patterns, which is a useful real-world counterweight to the raw percentage tables. Goetz 2025 A separate meta-analysis pooling three randomised trials (640 participants total) found retatrutide significantly increased non-severe gastrointestinal and hypersensitivity adverse events over placebo while confirming a mean weight reduction of 10.66 kg. Pasqualotto 2024 If you want a broader read on verifying what you are actually working with before you start tracking any of these effects, our guide on how to know if peptides are real covers the sourcing side of that question.

References

• Jastreboff et al. 2023, New England Journal of Medicine. NEJMoa2301972
• Rosenstock et al. 2023, PubMed. 37385280
• Abdrabou et al. 2025, PMC. PMC12026077
• Pasqualotto et al. 2024, PMC. PMC11420505
• Sanyal et al. 2024, PubMed. 38858523
• Goetz et al. 2025, PubMed. 41216380

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.